🚀 Make-or-break trials
Small companies on the stock market with one decisive trial result coming. The company is small and the trial is in its final phase, so this one result can transform the company, up or down. Every trial is explained in plain language.
Ranked by how much the result matters to the company: the smaller the company, the more decisive the trial, and the sooner the result, the higher it sits.
The weekly investor briefing
One email every Sunday: which trial results are due in the coming weeks, what read out in the past week, and the small companies with a make-or-break result ahead. Free, and every issue has a one-click unsubscribe.
We'll send one confirmation email first — you're not subscribed until you click it.
-
Gene therapy slows vision loss in stargardt disease trial
Disease control OngoingPhase 2/3 Pivotal Confirmatory Clinical Trial is a randomized, outcome assessor-masked, multicenter study, that will enroll fifty-one (51) subjects. Subjects will be enrolled in a 2:1 ratio to either the treatment group (n=34 subjects) or to an untreated control group (n=17 subje…
Results expected Sep 2026 (estimated)
Phase: PHASE2, PHASE3 • Sponsor: Ocugen • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
Ocugen · OCGN NASDAQ Trade on eToro (ad)Result impact 🚀 Make-or-breakMicro-cap May already have reported Readout in ~4 wkThe company has filed about this drug. The registry date may be out of date.
Sponsor filing, 2026-03-27 → -
New eye injection aims to stop vision loss in dry AMD patients
Disease control OngoingThe primary purpose of the study is to determine if IVT injections of vonaprument every month reduce vision loss in participants with dry AMD with GA.
Results expected Oct 2026 (estimated)
Phase: PHASE3 • Sponsor: Annexon, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
Annexon, Inc. · ANNX NASDAQ Trade on eToro (ad)Result impact 🚀 Make-or-breakMicro-cap Phase 3, decisive Readout in ~2 moA result this decisive could redraw a company this size.
-
New MS pill aims to slash relapses in major trial
Disease control OngoingMulti-Center, Randomized, Double-Blinded Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 versus Placebo in Adults with Relapsing Multiple Sclerosis (ENSURE-2)
Results expected Nov 2026 (estimated)
Phase: PHASE3 • Sponsor: Immunic AG • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
Immunic, Inc. · IMUX NASDAQ Trade on eToro (ad)Result impact 🚀 Make-or-breakMicro-cap Phase 3, decisive Readout in ~2 moA result this decisive could redraw a company this size.
-
New pill aims to stop MS relapses in its tracks
Disease control OngoingMulti-Center, Randomized, Double-Blinded Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 versus Placebo in Adults with Relapsing Multiple Sclerosis (ENSURE-1)
Results expected Nov 2026 (estimated)
Phase: PHASE3 • Sponsor: Immunic AG • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
Immunic, Inc. · IMUX NASDAQ Trade on eToro (ad)Result impact 🚀 Make-or-breakMicro-cap Phase 3, decisive Readout in ~2 moA result this decisive could redraw a company this size.
-
Peanut patch for toddlers: could a sticker ease allergy fears?
Disease control OngoingThe primary objective of this study is to assess the 6-month safety of DBV712 250 micrograms (mcg) in subjects 1 through 3 years of age with peanut allergy.
Results expected Nov 2026 (estimated)
Phase: PHASE3 • Sponsor: DBV Technologies • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
DBV Technologies · DBVT NASDAQ Trade on eToro (ad)Result impact 🚀 Make-or-breakMicro-cap Phase 3, decisive Readout in ~2 moA result this decisive could redraw a company this size.
-
New stroke drug aims to help patients missed by standard treatments
Disease control Recruiting nowThis is a Phase 2/3 study evaluating the safety and efficacy of DM199 (rinvecalinase alfa) in treating participants with moderate stroke severity, who present within 24 hours of Acute Ischemic Stroke (AIS) onset due to small and medium vessel occlusions. This study focuses on par…
Results expected Dec 2026 (estimated)
Phase: PHASE2, PHASE3 • Sponsor: DiaMedica Therapeutics Inc • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
DiaMedica Therapeutics Inc. · DMAC NASDAQ Trade on eToro (ad)Result impact 🚀 Make-or-breakMicro-cap Phase 3, decisive Readout in ~3 moA result this decisive could redraw a company this size.
-
New pill combo aims to tackle tough lymphoma when other treatments fail
Disease control OngoingThe purpose of this Phase 2/3 study is to evaluate efficacy and safety of the combination of selinexor and R-GDP (SR-GDP) in patients with RR DLBCL who are not intended to receive hematopoetic stem cell transplantation (HSCT) or chimeric antigen receptor T cell (CAR-T) therapy. T…
Results expected Dec 2026 (estimated)
Phase: PHASE2, PHASE3 • Sponsor: Karyopharm Therapeutics Inc • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
Karyopharm Therapeutics Inc · KPTI NASDAQ Trade on eToro (ad)Result impact 🚀 Make-or-breakMicro-cap Phase 3, decisive Readout in ~3 moA result this decisive could redraw a company this size.
-
New hepatitis c pill aims to cut treatment time in half
Disease control OngoingThe purpose of this study is to compare the efficacy and safety of BEM/RZR to SOF/VEL in adults with chronic HCV.
Results expected Sep 2026 (estimated)
Phase: PHASE3 • Sponsor: Atea Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
ATEA Pharmaceuticals, Inc. · AVIR NASDAQ Trade on eToro (ad)Result impact 🚀 Make-or-breakSmall-cap Phase 3, decisive Readout dueA result this decisive could redraw a company this size.
-
New hope for heart lining pain: can CardiolRx keep flare-ups away?
Disease control Recruiting nowMulti-center, randomized, double-blind, placebo-controlled, phase-3 Trial. Patients with a history of recurrent pericarditis who are being treated with an IL-1 blocker for at least 12 months, scheduled to be discontinued, will be approached for potential trial participation. Dou…
Results expected Sep 2026 (estimated)
Phase: PHASE3 • Sponsor: Cardiol Therapeutics Inc. • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
Cardiol Therapeutics Inc. · CRDL NASDAQ Trade on eToro (ad)Result impact 🚀 Make-or-breakMicro-cap Phase 3, decisive Readout in ~3 wkA result this decisive could redraw a company this size.
-
New hope for chronic hives: barzolvolimab in Late-Stage trial
Disease control OngoingThe purpose of this study is to establish the efficacy, safety and tolerability of barzolvolimab in adult participants with Chronic Spontaneous Urticaria (CSU) inadequately controlled by non-sedating second generation H1-antihistamines in comparison to placebo.
Results expected Oct 2026 (estimated)
Phase: PHASE3 • Sponsor: Celldex Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
Celldex Therapeutics · CLDX NASDAQ Trade on eToro (ad)Result impact 🚀 Make-or-breakSmall-cap Phase 3, decisive Readout in ~4 wkA result this decisive could redraw a company this size.
-
New gel could slash facial skin cancers in rare genetic condition
Disease control OngoingThe aim of this clinical study is to find out how well Patidegib Gel 2% works in preventing new basal cell carcinomas (BCCs) developing on the face of adults with Gorlin syndrome, and how safe Patidegib Gel 2% is to use. People who take part will apply either Patidegib Gel 2% or…
Results expected Oct 2026 (estimated)
Phase: PHASE3 • Sponsor: Sol-Gel Technologies, Ltd. • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
Sol-Gel Technologies, Ltd. · SLGL NASDAQ Trade on eToro (ad)Result impact 🚀 Make-or-breakMicro-cap Phase 3, decisive Readout in ~4 wkA result this decisive could redraw a company this size.
-
New hope for chronic hive sufferers: drug shows promise in major trial
Disease control OngoingThe purpose of this study is to establish the efficacy, safety and tolerability of barzolvolimab in adult participants with Chronic Spontaneous Urticaria (CSU) inadequately controlled by non-sedating second generation H1-antihistamines in comparison to placebo.
Results expected Oct 2026 (estimated)
Phase: PHASE3 • Sponsor: Celldex Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
Celldex Therapeutics · CLDX NASDAQ Trade on eToro (ad)Result impact 🚀 Make-or-breakSmall-cap Phase 3, decisive Readout in ~4 wkA result this decisive could redraw a company this size.
-
New eye drug could slash injection frequency for wet AMD patients
Disease control OngoingThis is a phase 3 randomized, double -masked study comparing the efficacy of EYP-1901 against Aflibercept.
Results expected Oct 2026 (estimated)
Phase: PHASE3 • Sponsor: EyePoint Pharmaceuticals, Inc. • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
EyePoint Pharmaceuticals, Inc. · EYPT NASDAQ Trade on eToro (ad)Result impact 🚀 Make-or-breakSmall-cap May already have reported Readout in ~4 wkThe company has filed about this drug. The registry date may be out of date.
Sponsor filing, 2026-08-17 → -
New pill could tame focal seizures when other drugs fail
Disease control Recruiting nowThe X-TOLE3 Phase 3 clinical trial is a randomized, double-blind, placebo-controlled study that will evaluate the clinical efficacy, safety and tolerability of XEN1101 administered as adjunctive therapy in focal-onset seizures.
Results expected Oct 2026 (estimated)
Phase: PHASE3 • Sponsor: Xenon Pharmaceuticals Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
Xenon Pharmaceuticals Inc. · XENE NASDAQ Trade on eToro (ad)Result impact 🚀 Make-or-breakSmall-cap Phase 3, decisive Readout in ~4 wkA result this decisive could redraw a company this size.
-
New hope for babies with rare seizure disorder: drug trial targets SCN2A gene
Disease control Recruiting nowA Multi-Center, Single-Arm Clinical Trial to Investigate the Efficacy and Safety of Elsunersen in Pediatric Participants with Early Onset SCN2A Developmental and Epileptic Encephalopathy
Results expected Dec 2026 (estimated)
Phase: PHASE3 • Sponsor: Praxis Precision Medicines • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
Praxis Precision Medicines · PRAX NASDAQ Trade on eToro (ad)Result impact 🚀 Make-or-breakMicro-cap Phase 3, decisive Readout in ~3 moA result this decisive could redraw a company this size.
-
New hope for kids with rare epilepsy: drug trial targets seizure control
Disease control OngoingA Phase 3, Randomized, Multi-Center, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Relutrigine in Participants with Developmental and Epileptic Encephalopathies Followed by an Open-Label Extension
Results expected Dec 2026 (estimated)
Phase: PHASE3 • Sponsor: Praxis Precision Medicines • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
Praxis Precision Medicines · PRAX NASDAQ Trade on eToro (ad)Result impact 🚀 Make-or-breakMicro-cap Phase 3, decisive Readout in ~3 moA result this decisive could redraw a company this size.
-
New epilepsy drug vormatrigine enters final testing phase
Disease control OngoingA multicenter, double-blind, randomized, placebo-controlled clinical trial to evaluate the efficacy and safety of vormatrigine in adults with focal seizures (POWER2)
Results expected Jan 2027 (estimated)
Phase: PHASE3 • Sponsor: Praxis Precision Medicines • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
Praxis Precision Medicines · PRAX NASDAQ Trade on eToro (ad)Result impact 🚀 Make-or-breakMicro-cap May already have reported Readout in ~4 moThe company has filed about this drug. The registry date may be out of date.
Sponsor filing, 2026-06-01 → -
New eye drug aims to restore vision in inflammatory swelling
Disease control Recruiting nowA Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants with Macular Edema Secondary to Inflammation (MESI)
Results expected Feb 2027 (estimated)
Phase: PHASE3 • Sponsor: Kodiak Sciences Inc • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
Kodiak Sciences · KOD NASDAQ Trade on eToro (ad)Result impact 🚀 Make-or-breakMicro-cap May already have reported Readout in ~5 moThe company has filed about this drug. The registry date may be out of date.
Sponsor filing, 2026-03-27 → -
One-Time gene therapy aims to restore muscle in boys with duchenne
Disease control OngoingRGX-202 is a gene therapy designed to deliver a transgene for a novel microdystrophin that includes functional elements of naturally-occurring dystrophin including the C-Terminal (CT) domain. This is a multicenter, open-label dose evaluation clinical study to assess the safety, …
Results expected Sep 2026 (estimated)
Phase: PHASE2, PHASE3 • Sponsor: REGENXBIO Inc. • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
RegenxBio Inc. · RGNX NASDAQ Trade on eToro (ad)Result impact 🚀 Make-or-breakSmall-cap Phase 3, decisive Readout dueA result this decisive could redraw a company this size.
-
New hep c combo aims to match top therapy in phase 3 showdown
Disease control OngoingThe purpose of this study is to compare the efficacy and safety of BEM/RZR to SOF/VEL in adults with chronic HCV.
Results expected Dec 2026 (estimated)
Phase: PHASE3 • Sponsor: Atea Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
ATEA Pharmaceuticals, Inc. · AVIR NASDAQ Trade on eToro (ad)Result impact 🚀 Make-or-breakSmall-cap Phase 3, decisive Readout in ~3 moA result this decisive could redraw a company this size.
-
New combo therapy shows promise for Tough-to-Treat bile duct cancer
Disease control OngoingThis is a multi-center, open-label, randomized, phase 2/3 trial of the bispecific antibody CTX-009 plus paclitaxel versus paclitaxel in patients with previously treated, unresectable advanced or metastatic biliary tract cancers.
Results expected Dec 2026 (estimated)
Phase: PHASE2, PHASE3 • Sponsor: Compass Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
COMPASS THERAPEUTICS · CMPX NASDAQ Trade on eToro (ad)Result impact 🚀 Make-or-breakMicro-cap Phase 3, decisive Readout in ~3 moA result this decisive could redraw a company this size.
-
Bladder cancer breakthrough? virus therapy aims to stop recurrence
Disease control OngoingThis is a Phase 3, open-label, randomized trial designed to evaluate the RFS of TURBT followed by cretostimogene grenadenorepvec versus TURBT followed by surveillance for the treatment of participants with IR-NMIBC.
Results expected Nov 2026 (estimated)
Phase: PHASE3 • Sponsor: CG Oncology, Inc. • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
CG Oncology, Inc. · CGON NASDAQ Trade on eToro (ad)Result impact 🚀 Make-or-breakSmall-cap May already have reported Readout in ~2 moThe company has filed about this drug. The registry date may be out of date.
Sponsor filing, 2026-01-09 → -
New eye injection shows promise for rare eye cancer
Disease control Recruiting nowA prospective, randomized, double-masked, dosing-frequency-controlled, multicenter clinical trial evaluating the safety and activity of intravitreally injected ADX-2191 (methotrexate injection USP) in patients with primary vitreoretinal lymphoma
Results expected Dec 2026 (estimated)
Phase: PHASE3 • Sponsor: Aldeyra Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
Aldeyra Therapeutics, Inc. · ALDX NASDAQ Trade on eToro (ad)Result impact 🚀 Make-or-breakMicro-cap Phase 3, decisive Readout in ~3 moA result this decisive could redraw a company this size.
-
New pill aims to calm social anxiety on the spot
Symptom relief OngoingThis is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of a single oral dose of VQW-765 compared to placebo in adults with social anxiety disorder.
Results expected Dec 2026 (estimated)
Phase: PHASE3 • Sponsor: Vanda Pharmaceuticals • Aim: Symptom relief
Last updated Aug 19, 2026 00:00 UTC
Vanda Pharmaceuticals · VNDA NASDAQ Trade on eToro (ad)Result impact 🚀 Make-or-breakSmall-cap Phase 3, decisive Readout in ~3 moA result this decisive could redraw a company this size.
-
Gene therapy trial aims to restore night vision in rare eye disease
Disease control OngoingThis is a Phase 3 study to Assess the Efficacy, Safety and Tolerability of OCU400 in patients with retinitis pigmentosa (RP) associated with RHO mutations and patients with any other RP associated mutation with a clinical phenotype of RP. This is a multicenter, assessor blinded …
Results expected Feb 2027 (estimated)
Phase: PHASE3 • Sponsor: Ocugen • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
Ocugen · OCGN NASDAQ Trade on eToro (ad)Result impact 🚀 Make-or-breakMicro-cap May already have reported Readout in ~5 moThe company has filed about this drug. The registry date may be out of date.
Sponsor filing, 2026-01-15 → -
New eye drug aims to restore vision in Inflammation-Related swelling
Disease control Recruiting nowA Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants with Macular Edema Secondary to Inflammation (MESI)
Results expected Apr 2027 (estimated)
Phase: PHASE3 • Sponsor: Kodiak Sciences Inc • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
Kodiak Sciences · KOD NASDAQ Trade on eToro (ad)Result impact 🚀 Make-or-breakMicro-cap May already have reported Readout in ~7 moThe company has filed about this drug. The registry date may be out of date.
Sponsor filing, 2026-03-27 → -
One-Shot stem cell treatment aims to quiet aching backs
Symptom relief OngoingThe primary purpose of this study is to evaluate the efficacy of rexlemestrocel-L+HA compared to control in reducing low back pain at 12 months post-treatment and safety of a single injection of rexlemestrocel-L+HA injected into a lumbar intervertebral disc compared to control th…
Results expected Jul 2027 (estimated)
Phase: PHASE3 • Sponsor: Mesoblast, Ltd. • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
Mesoblast, Ltd. · MESO NASDAQ Trade on eToro (ad)Result impact 🚀 Make-or-breakMicro-cap Phase 3, decisive Readout in ~10 moA result this decisive could redraw a company this size.
-
New pill aims to strengthen hearts in genetic cardiomyopathy
Disease control Recruiting nowThe Sponsor is studying an investigational medication called danicamtiv to determine if it can help people with genetic and familial dilated cardiomyopathy (DCM). Investigational means that the safety and effectiveness of danicamtiv have not been established. Currently, there are…
Results expected Sep 2027 (estimated)
Phase: PHASE2, PHASE3 • Sponsor: Kardigan, Inc. • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
Kardigan, Inc. · KARD NASDAQ Trade on eToro (ad)Result impact 🚀 Make-or-breakMicro-cap Phase 3, decisive Readout in ~1 yrA result this decisive could redraw a company this size.
-
Can a blister beetle extract banish common warts? phase 3 trial investigates
Disease control Not yet recruitingThis is a Phase 3, double-blind, randomized, vehicle-controlled study (Study number VP-CW-302; referred to as COVE-3 \[Cantharidin and Occlusion in Verruca Epithelium\]) to evaluate the efficacy and safety of YCANTH (VP-102/TO-208) treatment in subjects with common warts.
Results expected Aug 2027 (estimated)
Phase: PHASE3 • Sponsor: Verrica Pharmaceuticals Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:08 UTC
Verrica Pharmaceuticals Inc. · VRCA NASDAQ Trade on eToro (ad)Result impact 🚀 Make-or-breakMicro-cap Phase 3, decisive Readout in ~1 yrA result this decisive could redraw a company this size.
-
New drug cocktail aims to fight deadly eye cancer
Disease control OngoingThis is a Phase 2/3, multi-arm, multi-stage, open-label study of human leukocyte antigen (HLA)-A\*02:01 negative participants with metastatic uveal melanoma (MUM) who will be randomized to receive either IDE196 + crizotinib or investigator's choice of treatment (pembrolizumab, ip…
Results expected Jan 2027 (estimated)
Phase: PHASE2, PHASE3 • Sponsor: IDEAYA Biosciences • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
Ideaya Biosciences · IDYA NASDAQ Trade on eToro (ad)Result impact 🚀 Make-or-breakSmall-cap Phase 3, decisive Readout in ~5 moA result this decisive could redraw a company this size.
-
New drug could ease teen IBS constipation pain
Symptom relief OngoingThis is a randomized, double-blind, placebo-controlled study to assess the efficacy, safety and tolerability of tenapanor (25 mg and 50 mg) in pediatric patients (≥12 and \<18 years old) with IBS-C when administered twice daily (BID) for 12 consecutive weeks.
Results expected Sep 2026 (estimated)
Phase: PHASE3 • Sponsor: Ardelyx • Aim: Symptom relief
Last updated Jun 27, 2026 13:02 UTC
Ardelyx · ARDX NASDAQ Trade on eToro (ad)Result impact 🚀 Make-or-breakSmall-cap Phase 3, decisive Readout dueA result this decisive could redraw a company this size.
-
Could a new pill fix your body clock? phase 3 trial underway
Symptom relief OngoingThis is a multicenter, double-blind, randomized study to evaluate the efficacy and safety of a daily single oral dose of tasimelteon and matching placebo in male and female participants with DSWPD.
Results expected Sep 2026 (estimated)
Phase: PHASE3 • Sponsor: Vanda Pharmaceuticals • Aim: Symptom relief
Last updated Jul 29, 2026 00:00 UTC
Vanda Pharmaceuticals · VNDA NASDAQ Trade on eToro (ad)Result impact 🚀 Make-or-breakSmall-cap Phase 3, decisive Readout dueA result this decisive could redraw a company this size.
-
New hope for GBS: Single-Dose drug enters final testing
Disease control Recruiting nowThe goal of this open label study is to measure pharmacokinetics, pharmacodynamics, early efficacy, and safety of tanruprubart in adult and pediatric participants, in the United States, Canada, and Europe.
Results expected Dec 2026 (estimated)
Phase: PHASE3 • Sponsor: Annexon, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:39 UTC
Annexon, Inc. · ANNX NASDAQ Trade on eToro (ad)Result impact 🚀 Make-or-breakMicro-cap Phase 3, decisive Readout in ~4 moA result this decisive could redraw a company this size.
-
New eye implant could slow vision loss in diabetes
Disease control Recruiting nowThe purpose of this trial is to study the safety and effectiveness of OTX-TKI (axitinib intravitreal hydrogel) for the treatment of Non-Proliferative Diabetic Retinopathy. OTX-TKI is an intravitreal hydrogel embedded with axitinib. When the OTX-TKI hydrogel is administered into …
Results expected Mar 2027 (estimated)
Phase: PHASE3 • Sponsor: Ocular Therapeutix, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
Ocular Therapeutix, Inc. · OCUL NASDAQ Trade on eToro (ad)Result impact 🚀 Make-or-breakSmall-cap Phase 3, decisive Readout in ~6 moA result this decisive could redraw a company this size.
-
New gel could zap away common warts in just weeks
Disease control Recruiting nowThis is a Phase 3, double-blind, randomized, vehicle-controlled study (Study number VP-CW-301; referred to as COVE-2 \[Cantharidin and Occlusion in Verruca Epithelium\]) to evaluate the efficacy and safety of YCANTH (VP-102) treatment in subjects with common warts.
Results expected Jun 2027 (estimated)
Phase: PHASE3 • Sponsor: Verrica Pharmaceuticals Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
Verrica Pharmaceuticals Inc. · VRCA NASDAQ Trade on eToro (ad)Result impact 🚀 Make-or-breakMicro-cap Phase 3, decisive Readout in ~9 moA result this decisive could redraw a company this size.
-
New drug combo aims to tackle stubborn hepatitis d
Disease control OngoingThis is a multicenter, open label, randomized Phase 3 clinical study to evaluate tobevibart + elebsiran in participants with Chronic HDV Infection not virologically suppressed with bulevirtide
Results expected Dec 2026 (estimated)
Phase: PHASE3 • Sponsor: Vir Biotechnology, Inc. • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
Vir Biotechnology, Inc. · VIR NASDAQ Trade on eToro (ad)Result impact 🚀 Make-or-breakSmall-cap Phase 3, decisive Readout in ~3 moA result this decisive could redraw a company this size.
-
New combo therapy aims to outsmart resistant blood cancer
Disease control Recruiting nowThis is a global multicenter, open label, randomized, registrational phase III study to investigate the efficacy and safety of lisaftoclax in combination with BTK inhibitors in CLL/SLL patients who previously treated with BTK inhibitors
Results expected Dec 2026 (estimated)
Phase: PHASE3 • Sponsor: Ascentage Pharma Group Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
Ascentage Pharma Group Inc. · AAPG NASDAQ Trade on eToro (ad)Result impact 🚀 Make-or-breakSmall-cap Phase 3, decisive Readout in ~4 moA result this decisive could redraw a company this size.
-
Could a diabetes drug help heart muscle disease? large trial underway
Symptom relief OngoingThe main purpose of the study is to determine the changes in symptoms and functional limitations in participants with symptomatic hypertrophic cardiomyopathy (HCM) treated with sotagliflozin as compared to placebo.
Results expected Jan 2027 (estimated)
Phase: PHASE3 • Sponsor: Lexicon Pharmaceuticals • Aim: Symptom relief
Last updated Aug 28, 2026 00:00 UTC
Lexicon Pharmaceuticals · LXRX NASDAQ Trade on eToro (ad)Result impact 🚀 Make-or-breakSmall-cap Phase 3, decisive Readout in ~4 moA result this decisive could redraw a company this size.
-
New dosing strategy for MS drug ublituximab under study in 800-Patient trial
Disease control Recruiting nowThe primary purpose of this phase 3b study is to assess the efficacy of a modified regimen of ublituximab in participants with relapsing multiple sclerosis (RMS) as measured by T1 Gadolinium (Gd)-enhancing lesions in Part A; PK in Part B along with efficacy of ublituximab as meas…
Results expected Jan 2027 (estimated)
Phase: PHASE3 • Sponsor: TG Therapeutics, Inc. • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
TG Therapeutics, Inc. · TGTX NASDAQ Trade on eToro (ad)Result impact 🚀 Make-or-breakSmall-cap Phase 3, decisive Readout in ~5 moA result this decisive could redraw a company this size.
-
CAR t therapy takes on myasthenia gravis in major new trial
Disease control Recruiting nowA Study of the Anti-CD 19 Chimeric Antigen Receptor T Cell Therapy for Patients with Myasthenia Gravis
Results expected Sep 2027 (estimated)
Phase: PHASE2, PHASE3 • Sponsor: Kyverna Therapeutics • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
Kyverna Therapeutics · KYTX NASDAQ Trade on eToro (ad)Result impact 🚀 Make-or-breakMicro-cap Phase 3, decisive Readout in ~1 yrA result this decisive could redraw a company this size.
-
New hope for kids with rare immune disease: drug targets root cause
Disease control OngoingThis is a 2-part, prospective, open-label, single arm, multicenter study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and efficacy of leniolisib in at least 15 pediatric patients (aged 4 to 11 years) with activated phosphoinositide 3-kinase…
Results expected Nov 2026 (estimated)
Phase: PHASE3 • Sponsor: Pharming Technologies B.V. • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
Pharming Group N.V. · PHAR NASDAQ Trade on eToro (ad)Result impact 🚀 Make-or-breakSmall-cap Phase 3, decisive Readout in ~3 moA result this decisive could redraw a company this size.
-
New drug aims to ease chronic constipation in large trial
Symptom relief Recruiting nowThis is a 26-week, multi-center, randomized, double-blind, placebo-controlled study with a 4-week treatment-free Safety Follow-up period to assess the safety and efficacy of tenapanor (5 mg, 25mg, and 50 mg) in adult patients with Chronic Idiopathic Constipation (CIC) when admini…
Results expected Feb 2027 (estimated)
Phase: PHASE3 • Sponsor: Ardelyx • Aim: Symptom relief
Last updated Jun 27, 2026 13:03 UTC
Ardelyx · ARDX NASDAQ Trade on eToro (ad)Result impact 🚀 Make-or-breakSmall-cap Phase 3, decisive Readout in ~6 moA result this decisive could redraw a company this size.
-
One shot to save sight? gene therapy aims to cut eye injections for wet AMD
Disease control OngoingA Phase 3, Randomized, Double-Masked, Active-Controlled Trial in Adults with Macular Neovascularization Secondary to Age-Related Macular Degeneration
Results expected Jun 2027 (estimated)
Phase: PHASE3 • Sponsor: 4D Molecular Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
4D Molecular Therapeutics · FDMT NASDAQ Trade on eToro (ad)Result impact 🚀 Make-or-breakSmall-cap Phase 3, decisive Readout in ~9 moA result this decisive could redraw a company this size.
-
Can a Chemo-Free pill combo outsmart leukemia at first diagnosis?
Disease control Recruiting nowThis is a global, multicenter, randomized, open-label, Phase III confirmatory study to investigate the efficacy and safety of Lisaftoclax (APG-2575) in combination with Acalabrutinib in patients with newly diagnosed CLL/SLL.
Results expected Aug 2027 (estimated)
Phase: PHASE3 • Sponsor: Ascentage Pharma Group Inc. • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
Ascentage Pharma Group Inc. · AAPG NASDAQ Trade on eToro (ad)Result impact 🚀 Make-or-breakSmall-cap Phase 3, decisive Readout in ~1 yrA result this decisive could redraw a company this size.
-
New pill aims to slash severe hypoglycemia in type 1 diabetes
Disease control OngoingThis is a Phase 3 trial of cadisegliatin as adjunctive therapy to insulin in participants with Type 1 Diabetes Mellitus.
Results expected Apr 2027 (estimated)
Phase: PHASE3 • Sponsor: vTv Therapeutics • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
vTv Therapeutics · VTVT NASDAQ Trade on eToro (ad)Result impact 🚀 Make-or-breakMicro-cap Phase 3, decisive Readout in ~7 moA result this decisive could redraw a company this size.
-
Could an old asthma drug slow ALS? new trial aims to find out
Disease control OngoingA Phase 2b/3 multicenter, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy, safety and tolerability of MN-166 given to ALS participants for 12 months followed by a 6-month open-label extension phase.
Results expected Apr 2027 (estimated)
Phase: PHASE2, PHASE3 • Sponsor: MediciNova • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
MediciNova · MNOV NASDAQ Trade on eToro (ad)Result impact 🚀 Make-or-breakMicro-cap Phase 3, decisive Readout in ~7 moA result this decisive could redraw a company this size.
-
New hope for muscle weakness: drug trial targets myasthenia gravis
Disease control Recruiting nowThe purpose of this study is to evaluate the efficacy and safety of telitacicept in the treatment of generalized myasthenia gravis.
Results expected May 2027 (estimated)
Phase: PHASE3 • Sponsor: Vor Biopharma • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
Vor Biopharma · VOR NASDAQ Trade on eToro (ad)Result impact 🚀 Make-or-breakMicro-cap May already have reported Readout in ~8 moThe company has filed about this drug. The registry date may be out of date.
Sponsor filing, 2026-06-08 → -
Lab-Made blood vessel could free dialysis patients from catheters
Disease control OngoingThe goal of this clinical trial is to compare the number of catheter-free days (CFD) and the rate and severity of any dialysis access-related infections between the ATEV and AVF groups over 12 months in patients with end-stage renal disease (ESRD) needing hemodialysis (HD). Part…
Results expected Jun 2027 (estimated)
Phase: PHASE3 • Sponsor: Humacyte, Inc. • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
Humacyte, Inc. · HUMA NASDAQ Trade on eToro (ad)Result impact 🚀 Make-or-breakMicro-cap Phase 3, decisive Readout in ~9 moA result this decisive could redraw a company this size.
-
New drug aims to boost immune cells in rare blood disorder
Disease control Recruiting nowThe purpose of this study is to demonstrate the efficacy and evaluate the safety and tolerability of mavorixafor in participants with congenital or acquired primary autoimmune and idiopathic chronic neutropenic disorders who are experiencing recurrent and/or serious infections as…
Results expected Sep 2027 (estimated)
Phase: PHASE3 • Sponsor: X4 Pharmaceuticals • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
X4 Pharmaceuticals · XFOR NASDAQ Trade on eToro (ad)Result impact 🚀 Make-or-breakMicro-cap Phase 3, decisive Readout in ~1 yrA result this decisive could redraw a company this size.
-
New pill aims to stop nausea caused by popular Weight-Loss drugs
Symptom relief Recruiting nowThe goal of this study is to measure the effects of using Tradipitant to treat nausea and vomiting induced by GLP-1R agonist use in adults with class I or class II obesity, or adults who are overweight with at least one weight-related condition. The study is placebo-controlled wi…
Results expected Dec 2026 (estimated)
Phase: PHASE3 • Sponsor: Vanda Pharmaceuticals • Aim: Symptom relief
Last updated Jun 27, 2026 12:10 UTC
Vanda Pharmaceuticals · VNDA NASDAQ Trade on eToro (ad)Result impact 🚀 Make-or-breakSmall-cap Phase 3, decisive Readout in ~3 moA result this decisive could redraw a company this size.
Why cures and vaccines come first here
We built this site so people can find trials that might cure them. These investor pages work toward the same goal from the money side: they show companies working on cures and vaccines first, and we promote those companies on purpose. We believe investor interest in cures and vaccines means more money for the companies chasing them, and more cure and vaccine trials as a result.
Nothing is hidden by this. Every trial soon ready, whatever its aim, is on the full list . Rankings are computed from the public trial record and the company's size. No company can pay to be listed or ranked higher.
Not investment advice. This page lists publicly registered clinical trials and the companies running them, for information only. A trial finishing is not a result, and a result is not an approval. Clinical trials frequently fail, and small companies fail with them.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. We think this page is more useful when you can go straight to somewhere that sells the stock, so it shows only companies our broker partner carries; the full list of trials soon ready is unfiltered. Ranking is never for sale: no company can pay to appear here or to place higher.